<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>RELEBACTAM - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for RELEBACTAM">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>RELEBACTAM</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>RELEBACTAM</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Relebactam functions by covalently binding to bacterial β-lactamase enzymes, particularly class A and class C β-lactamases. Relebactam irreversibly regulates class A and class C β-lactamases through covalent binding. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. It was developed through rational drug design rather than isolation from natural sources. No documentation exists of traditional medicine use, as this is a recently developed pharmaceutical compound. Relebactam is not produced via fermentation or biosynthetic methods and rather through pharmaceutical synthesis.</p>

<h3>Structural Analysis</h3> Relebactam is structurally classified as a diazabicyclooctane (DBO) β-lactamase inhibitor. While it works to share direct structural similarity to naturally occurring compounds, it contains functional groups found in natural molecules including amide bonds and nitrogen-containing heterocycles. It is not related to endogenous human compounds and targets bacterial enzymes that have evolved resistance mechanisms. Its metabolic products have not been extensively characterized for natural analogs.

<h3>Biological Mechanism Evaluation</h3> Relebactam functions by covalently binding to bacterial β-lactamase enzymes, particularly class A and class C β-lactamases. While it works to interact with endogenous human receptors or pathways directly, it preserves the activity of co-administered β-lactam antibiotics by preventing bacterial resistance mechanisms. It works to supplement natural human substances and rather targets bacterial defensive enzymes to restore antibiotic effectiveness.

<h3>Natural System Integration</h3> (Expanded Assessment) Relebactam targets bacterial β-lactamase enzymes, which are naturally occurring bacterial defense mechanisms that have evolved over millions of years. By inhibiting these enzymes, it restores the effectiveness of β-lactam antibiotics against resistant bacteria. This mechanism removes obstacles to natural healing processes by enabling the immune system to function more effectively alongside antibiotic therapy. It works within the context of bacterial-host interactions and can prevent the need for more invasive interventions by restoring first-line antibiotic effectiveness. The compound facilitates return to natural physiological balance by eliminating bacterial infections that disrupt homeostasis.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Relebactam irreversibly regulates class A and class C β-lactamases through covalent binding. It forms a stable complex with the enzyme, preventing it from hydrolyzing β-lactam antibiotics. This mechanism restores the bactericidal activity of β-lactam antibiotics against resistant bacterial strains. The compound works synergistically with imipenem-cilastatin to overcome bacterial resistance mechanisms.</p>

<h3>Clinical Utility</h3> Relebactam is approved in combination with imipenem-cilastatin for treatment of complicated urinary tract infections and complicated intra-abdominal infections caused by susceptible bacteria. It addresses the critical need for effective treatments against multidrug-resistant gram-negative bacteria. The safety profile is generally favorable with gastrointestinal and infusion-related reactions being the most common adverse effects. It is intended for short-term use during acute bacterial infections.

<h3>Integration Potential</h3> Relebactam shows compatibility with naturopathic principles as it works to restore the effectiveness of existing antibiotics rather than introducing entirely novel mechanisms. It can be integrated into comprehensive treatment plans that include immune support and microbiome restoration therapies. The compound creates a therapeutic window for natural interventions by rapidly controlling bacterial infections. Practitioners require education on appropriate use for resistant infections and combination with supportive therapies.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Relebactam is FDA-approved as part of the combination product imipenem-cilastatin-relebactam (Recarbrio) since July 2019. It has received approval from the European Medicines Agency and other international regulatory bodies. It is not currently listed on the WHO Essential Medicines List, as it is a relatively new addition to the antimicrobial arsenal.</p>

<h3>Comparable Medications</h3> Other β-lactamase inhibitors such as clavulanic acid and sulbactam are included in various naturopathic formularies. Avibactam, another DBO β-lactamase inhibitor, shares structural and functional similarities with relebactam. The acceptance of other combination β-lactam/β-lactamase inhibitor products provides precedent for this class of medications.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>RELEBACTAM</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Direct natural source</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Relebactam is a laboratory-produced compound with laboratory-produced compound or derivation. Additionally, it demonstrates significant integration with natural biological systems through its mechanism of targeting bacterial enzymes and enabling natural healing processes.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>While not structurally similar to natural compounds, relebactam targets β-lactamase enzymes that are naturally occurring bacterial proteins. The compound&#x27;s functional relationship exists with the evolutionarily conserved bacterial resistance mechanisms it regulates.</p><p><strong>Biological Integration:</strong></p>

<p>Relebactam integrates with natural host-pathogen interactions by disabling bacterial defense mechanisms, thereby allowing both administered antibiotics and natural immune responses to function more effectively against resistant bacteria.</p><p><strong>Natural System Interface:</strong></p>

<p>This synthetic medication works within the naturally occurring bacterial enzyme systems, specifically targeting class A and class C β-lactamases. It restores physiological balance by eliminating pathogenic bacteria that disrupt normal bodily functions, enabling the immune system and natural healing processes to restore health.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Generally well-tolerated with primarily gastrointestinal and infusion-site reactions. Provides a less invasive alternative to broader-spectrum or more toxic antimicrobial agents by restoring the effectiveness of established β-lactam antibiotics.</p><p><strong>Summary of Findings:</strong></p>

<p>RELEBACTAM provides essential therapeutic benefits through mechanisms that integrate with natural physiological processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>DrugBank Online. &quot;Relebactam.&quot; DrugBank Accession Number DB11638. Version 5.1.11, released 2024-01-04. https://go.drugbank.com/drugs/DB11638 2. PubChem. &quot;Relebactam.&quot; PubChem CID: 46926350. National Center for Biotechnology Information, National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/46926350 3. U.S. Food and Drug Administration. &quot;RECARBRIO (imipenem, cilastatin, and relebactam) for injection, for intravenous use: Prescribing Information.&quot; Initial approval July 16, 2019. Reference ID: 4464855.</li>

<li>Hecker SJ, Reddy KR, Lomovskaya O, Griffith DC, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Parkinson J, Totrov M, Boyer SH, Glinka TW, Pemberton OA, Chen Y, Dudley MN. &quot;Discovery of Cyclic Boronic Acid QPX7728, an Ultra-Broad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.&quot; Journal of Medicinal Chemistry. 2020;63(14):7491-7507.</li>

<li>Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. &quot;In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative ESKAPE pathogens isolated in hospital laboratories in the United States between 2015 and 2017 - SMART 2015-2017.&quot; European Journal of Clinical Microbiology &amp; Infectious Diseases. 2020;39(7):1321-1331.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>